PACB PACIFIC BIOSCIENCES OF CALIFORNIA, INC.

CIK 0001299130 50 ready 8-Ks latest August 5, 2026, 4:23 PM ET RSS · JSON

Activity: NORMAL 1 filings / 30d vs 1 baseline

Ready 8-Ks 50

Latest filing August 5, 2026, 4:23 PM ET

Top materiality 0.85

Event mix earnings ×21 · leadership ×12 · other_material ×9

Sentiment 10 pos · 13 neg · 27 neu

Latest earnings reported 2026-Q1

Executive change recent →

Recent 8-K filings for PACB

Highest-materiality recent filing

PacBio Q2 revenue $39M, net loss $44.7M; CEO Henry steps down, Van Oene appointed; restructuring cuts 8% workforce

August 5, 2026, 4:23 PM ET earnings materiality 0.85 negative item 2.02 item 2.05 item 5.02 item 7.01 item 9.01

Q2 revenue $39.0M (down 2% YoY); GAAP net loss $44.7M ($0.14 loss per share); non-GAAP net loss $41.9M.
Revio placements 20, Vega placements 26; consumable revenue $20.1M; annualized Revio pull-through ~$202K.

Read filing →

August 5, 2026, 4:23 PM ET earnings materiality 0.85 negative item 2.02 item 2.05 item 5.02 item 7.01 item 9.01

PacBio Q2 revenue $39M, net loss $44.7M; CEO Henry steps down, Van Oene appointed; restructuring cuts 8% workforce

Q2 revenue $39.0M (down 2% YoY); GAAP net loss $44.7M ($0.14 loss per share); non-GAAP net loss $41.9M.
July 9, 2026, 4:32 PM ET leadership materiality 0.35 neutral item 5.02

Director Christopher M. Smith resigns from Pacific Biosciences board effective July 8, 2026

Christopher M. Smith resigned from the Board effective July 8, 2026.
June 4, 2026, 5:19 PM ET other material materiality 0.50 neutral item 5.02 item 5.07 item 9.01 ◈ Shareholder Votes ×4

Shareholders approve 16M share increase in equity plan at Pacific Biosciences annual meeting

Stockholders approved amendment to 2020 Equity Incentive Plan, adding 16,000,000 shares for future grants.
May 7, 2026, 7:59 PM ET earnings materiality 0.65 neutral item 2.02 item 9.01 ◈ Earnings Releases

PacBio Q1 rev flat at $37.2M; consumable record but instrument miss; FY26 guidance $165-175M

Q1 revenue $37.2M flat YoY; consumable record $21.8M (+8% YoY), instrument revenue $9.7M (-12% YoY) below expectations.
March 6, 2026, 6:59 PM ET litigation materiality 0.60 neutral item 5.02 item 7.01

PACB settles patent lawsuit with PGI, will pay $23M to $25M; CAO resigns

Michele Farmer resigns as CAO effective March 21, 2026; no severance or disagreement.
March 5, 2026, 6:59 PM ET leadership materiality 0.40 positive item 5.02 item 7.01 item 9.01

PacBio appoints Chris Gibson (Recursion co-founder) to board; effective March 3, 2026

Board expanded to 10; Gibson appointed Class I director with term expiring at 2026 annual meeting.
February 12, 2026, 6:59 PM ET earnings materiality 0.80 neutral item 2.02 item 9.01

PacBio Q4 revenue $44.6M, consumable record; GAAP net loss $40.4M, non-GAAP loss narrows

Q4 revenue $44.6M (+14% YoY); consumable revenue record $21.6M (+15% YoY).
February 3, 2026, 6:59 PM ET leadership materiality 0.30 neutral item 5.02

Pacific Biosciences CEO and COO swap interim responsibilities effective Jan 28, 2026

CEO Christian Henry assumes interim oversight of operations and R&D from COO Mark Van Oene.
February 2, 2026, 6:59 PM ET M&A materiality 0.75 positive item 1.01 item 2.01 item 7.01 item 9.01 ◈ M&A Transactions

PacBio completes sale of short-read sequencing assets to Illumina for $48.1M net cash

Sold certain short-read DNA sequencing IP and related technologies to Illumina for $50M gross; net cash proceeds $48.1M.
January 12, 2026, 6:59 PM ET earnings materiality 0.75 positive item 2.02 item 8.01 item 9.01

PacBio Q4 revenue $44.6M (+14% YoY); full year $160M (+4%); record consumables

Q4 2025 revenue ~$44.6M vs $39.2M YoY; full year ~$160M vs $154M.
November 5, 2025, 6:59 PM ET earnings materiality 0.75 neutral item 2.02 item 9.01

PacBio Q3 revenue $38.4M, net loss narrows to $38M; consumables hit record $21.3M

GAAP net loss $38.0M ($0.13 loss per share) vs $60.7M ($0.22) YoY; non-GAAP net loss $36.8M ($0.12).
August 7, 2025, 7:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01

PacBio Q2 revenue up 10.5% YoY to $39.8M; GAAP net loss narrows to $41.9M

GAAP net loss per share of $0.14 improved from $0.64 YoY; non-GAAP EPS -$0.13 vs -$0.20.
June 6, 2025, 7:59 PM ET other materiality 0.60 neutral item 5.02 item 5.07 item 9.01

Stockholders approve 23M share increase to 2020 Equity Plan; Annual meeting results

Stockholders approved 23M share increase to 2020 Equity Plan: 85.4M for, 43.6M against, 56.4M broker non-votes.
May 8, 2025, 7:59 PM ET earnings materiality 0.75 negative item 2.02 item 9.01

PacBio Q1 GAAP net loss $426M on restructuring; consumable revenue record, non-GAAP loss narrows

Revenue $37.2M, down 4% YoY; consumable revenue record $20.1M (+26% YoY).
April 9, 2025, 7:59 PM ET earnings materiality 0.70 negative item 2.02 item 2.05 item 9.01 ◈ Restructurings & Charges

PacBio reports preliminary Q1 revenue $36.9M, down 5% YoY; cuts annual opex run rate by $45-50M

Preliminary Q1 2025 revenue $36.9M vs $38.8M YoY; instrument revenue fell to $10.8M from $19.0M.
March 27, 2025, 7:59 PM ET leadership materiality 0.50 positive item 5.02 item 7.01 item 9.01 ◈ executive_change ×2

PacBio appoints Jim Gibson as CFO, effective March 31, 2025

Jim Gibson appointed CFO effective March 31, 2025; Christian Henry ceases as interim CFO.
March 13, 2025, 7:59 PM ET other material materiality 0.55 neutral item 1.01 item 2.03 ◈ Debt Financings

Pacific Biosciences extends Menlo Park lease to 2034, gets $11.6M rent abatement

Lease term extended to April 30, 2034 from Oct 31, 2027; 180,231 sq ft.
February 13, 2025, 6:59 PM ET earnings materiality 0.80 negative item 2.02 item 9.01

PacBio Q4 rev $39.2M (-33% YoY), $90M impairment, non-GAAP loss $55.3M

Revenue $39.2M vs $58.4M prior year; instrument revenue fell to $15.3M from $35.1M.
February 7, 2025, 6:59 PM ET leadership materiality 0.15 neutral item 5.02

Pacific Biosciences appoints Smith to Science & Technology Committee, Mohr as Audit chair

Christopher M. Smith appointed to Science and Technology Committee effective February 6, 2024.
January 30, 2025, 6:59 PM ET leadership materiality 0.30 neutral item 5.02 item 7.01 item 9.01 ◈ executive_change ×2

PacBio appoints NeoGenomics CEO Chris Smith to board; David Meline resigns

Chris Smith, CEO of NeoGenomics (NEO), appointed to PacBio Board effective Jan 30, 2025.
January 14, 2025, 6:59 PM ET other material materiality 0.70 negative item 2.02 item 8.01 item 9.01

PacBio reports preliminary Q4 revenue $39.2M, down 33% YoY; Vega system shipped ahead of schedule

Preliminary Q4 revenue $39.2M vs $58.4M prior year (-33%); full year $154M vs $200M (-23%).
December 13, 2024, 6:59 PM ET leadership materiality 0.50 neutral item 5.02 item 9.01

Pacific Biosciences discloses CCO Jeff Eidel's separation terms: $485K severance, 12-month COBRA

Jeff Eidel's employment as CCO ended Nov 15, 2024; separation agreement signed Dec 6, effective Dec 13.
December 13, 2024, 6:59 PM ET other material materiality 0.50 neutral item 5.02

Pacific Biosciences amends CEO/COO severance: lump sum 12-18 months salary, extended change-of-control window

CEO Christian Henry receives lump sum cash severance equal to 18 months of base salary.
December 6, 2024, 6:59 PM ET leadership materiality 0.60 neutral item 5.02

Pacific Biosciences CFO Susan G. Kim resigns; CEO Christian Henry appointed interim CFO

Susan G. Kim resigned as CFO and principal financial officer effective December 6, 2024.
November 22, 2024, 6:59 PM ET debt materiality 0.80 neutral item 1.01 item 2.03 item 3.02 item 9.01

Pacific Biosciences exchanges $459M 2028 notes for $200M new notes, shares, and $50M cash

Exchanged $459M of 1.50% 2028 notes for $200M new 1.50% notes due 2029, 20,451,570 shares, and $50M cash.
November 12, 2024, 6:59 PM ET leadership materiality 0.50 neutral item 5.02 ◈ executive_change

Pacific Biosciences CCO Jeff Eidel to depart Nov 15 amid commercial restructuring

Jeff Eidel notified of separation as Chief Commercial Officer on November 11, 2024.
November 7, 2024, 6:59 PM ET debt materiality 0.70 positive item 1.01 item 2.03 item 8.01 item 3.02 item 9.01

PacBio exchanges $459M 2028 notes for $200M 2029 notes, 20.5M shares, $50M cash

Exchanged $459M of 1.5% 2028 notes for $200M new 1.5% 2029 notes, 20.45M shares, and $50M cash.
November 7, 2024, 6:59 PM ET earnings materiality 0.75 negative item 2.02 item 5.02 item 9.01 ◈ executive_change

PacBio Q3 revenue falls 28% to $40M; CFO resigns; notes exchange with SoftBank

Revenue $40.0M (-28% YoY); instrument revenue $16.8M (down from $34.7M); 22 Revio systems shipped.
August 7, 2024, 7:59 PM ET other material materiality 0.70 negative item 2.05 ◈ Restructurings & Charges

Pacific Biosciences estimates $27M in charges for expense reduction plan; San Diego office closure

Total charges estimated at $27M in fiscal 2024, including $10M compensation, $12M lease costs, $4M inventory.
August 7, 2024, 7:59 PM ET earnings materiality 0.75 negative item 2.02 item 9.01

PacBio Q2 revenue down 24% to $36M; GAAP net loss $173M includes $93M goodwill impairment

Revenue of $36.0M vs $47.6M YoY; instrument revenue fell to $14.7M from $29.9M.
June 20, 2024, 7:59 PM ET other material materiality 0.60 neutral item 5.02 item 5.07 item 5.03 item 9.01

PACB shareholders approve 20M share increase, board declassification, officer exculpation

Stockholders approved amendment to 2020 Equity Incentive Plan, adding 20,000,000 shares for issuance.
May 9, 2024, 7:59 PM ET earnings materiality 0.80 negative item 2.02 item 9.01 ◈ Earnings Releases ×2

PacBio Q1 revenue flat at $38.8M; net loss $78.2M; cuts 195 jobs to reduce expenses

Revenue $38.8M (flat YoY); instrument revenue down 8% to $19.0M; consumables up 14% to $16.0M.
April 16, 2024, 7:59 PM ET earnings materiality 0.85 negative item 2.02 item 2.05 item 8.01 item 9.01 ◈ Earnings Releases ×2

PacBio reports preliminary Q1 rev $38.8M (flat YoY), slashes FY2024 guidance to $170-200M, cuts costs $50-75M

Preliminary Q1 2024 revenue $38.8M, roughly flat vs $38.9M in prior-year period.
February 15, 2024, 6:59 PM ET earnings materiality 0.75 neutral item 2.02 item 9.01 ◈ Earnings Releases ×2

PacBio Q4 rev $58.4M (+113% YoY) but GAAP gross margin drops to 16%; FY rev $200.5M

Q4 revenue $58.4M (+113% YoY); instrument revenue $35.1M vs $6.1M YoY.
January 8, 2024, 6:59 PM ET earnings materiality 0.75 positive item 2.02 item 8.01 item 9.01 ◈ Earnings Releases ×2

PacBio reports record preliminary Q4 revenue $58.4M, up 113% YoY; Revio installed base 173

Preliminary full year 2023 revenue $200.5M, up 56% YoY; Q4 revenue $58.4M (+113% YoY).
December 11, 2023, 6:59 PM ET leadership materiality 0.35 neutral item 5.02 ◈ executive_change

Director David Botstein resigns from Pacific Biosciences board effective Dec 7, 2023

David Botstein notified the board of his resignation, effective December 7, 2023.
October 30, 2023, 7:59 PM ET earnings materiality 0.80 neutral item 2.02 item 9.01 ◈ Earnings Releases

PacBio Q3 revenue $55.7M (+72% YoY); net loss narrows to $66.9M

Revenue $55.7M, up 72% YoY; instrument revenue $34.7M from 52 Revio systems (prior year $11.4M).
October 27, 2023, 7:59 PM ET leadership materiality 0.20 neutral item 5.02

Pacific Biosciences appoints David Meline to Audit Committee

Board appointed David Meline to Audit Committee, effective October 24, 2023.
October 16, 2023, 7:59 PM ET leadership materiality 0.55 positive item 5.02 item 7.01 item 9.01 ◈ executive_change

PacBio appoints former Moderna CFO David Meline to board of directors

David Meline appointed as Class II director effective October 13, 2023, term expiring at 2024 annual meeting.
September 22, 2023, 7:59 PM ET M&A materiality 0.60 neutral item 3.02

Pacific Biosciences to issue ~8.9M shares and $101M cash for Omniome milestone

On Sep 20, 2023, PacBio achieved a commercial milestone under the Omniome merger agreement.
August 2, 2023, 7:59 PM ET earnings materiality 0.80 neutral item 2.02 item 3.02 item 7.01 item 9.01 ◈ Earnings Releases

PacBio Q2 revenue $47.6M (+34% YoY); acquires Apton for up to $110M; Onso shipments start

Q2 revenue $47.6M (+34% YoY); Revio drove record revenue with 45 systems shipped.
June 30, 2023, 7:59 PM ET debt materiality 0.60 neutral item 1.01 item 2.03 item 3.02 item 9.01 ◈ Debt Financings◈ Material Agreements

Pacific Biosciences exchanges $441M of 2028 notes for new 1.375% 2030 convertible notes

Issued $441M principal of 1.375% Convertible Senior Notes due 2030 in exchange for $441M of 1.50% 2028 Notes.
June 26, 2023, 7:59 PM ET debt materiality 0.75 positive item 1.01 item 2.03 item 8.01 item 3.02 item 9.01

PacBio exchanges $441M of 1.50% 2028 notes for $441M of 1.375% 2030 notes with Chimera

Exchanged $441M of 1.50% 2028 Convertible Notes for $441M of new 1.375% 2030 Convertible Notes with Chimera Investment LLC.
May 26, 2023, 7:59 PM ET other material materiality 0.15 neutral item 5.07 ◈ Shareholder Votes ×5

Pacific Biosciences stockholders reject classified board retention in advisory vote

Elected Class I directors Henry, Milligan, Shapiro with >178M votes each for three-year terms.
May 2, 2023, 7:59 PM ET earnings materiality 0.70 positive item 2.02 item 9.01 ◈ Earnings Releases

PacBio reports record Q1 revenue $38.9M (+17% YoY) but net loss widens to $88.0M

Q1 revenue $38.9M (+17% YoY); net loss $88.0M ($0.36 loss per share) vs $81.5M loss prior year.
February 16, 2023, 6:59 PM ET earnings materiality 0.75 negative item 2.02 item 9.01 ◈ Earnings Releases

PacBio Q4 revenue down 24% YoY to $27.4M; net loss $84.4M; record Revio orders

Q4 2022 GAAP net loss $84.4M ($0.37 EPS) vs $69.3M loss ($0.31 EPS) a year ago.
January 27, 2023, 6:59 PM ET other material materiality 0.75 neutral item 1.01 item 8.01 item 9.01 ◈ Material Agreements

PacBio prices 17.5M-share offering at $10/shr; expected net proceeds ~$189.2M

Sold 17.5M shares plus full exercise of underwriter option for 2.625M additional shares at $10.00 per share.
January 24, 2023, 6:59 PM ET other material materiality 0.75 negative item 2.02 item 8.01 item 9.01

PacBio announces $150M public stock offering to fund R&D, commercial expansion

Proposed offering of $150M common stock; underwriters have 30-day option for additional $22.5M.
January 9, 2023, 6:59 PM ET earnings materiality 0.75 neutral item 2.02 item 8.01 item 9.01 ◈ Earnings Releases

PacBio reports Q4 preliminary revenue $27.3M (-24% YoY); received orders for 76 Revio systems

Q4 2022 preliminary revenue $27.3M, down 24% from $36.0M in Q4 2021.
November 7, 2022, 6:59 PM ET earnings materiality 0.75 negative item 2.02 item 5.03 item 9.01 ◈ Earnings Releases◈ Governance Changes

PacBio Q3 2022 revenue down 7% YoY to $32.3M; net loss $77M; withdraws guidance; launches Revio and Onso systems

Revenue $32.3M (down 7% YoY); instrument revenue $11.4M (down 28%); consumables revenue $16.1M (up 10%).